vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and ONESPAWORLD HOLDINGS Ltd (OSW). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $242.1M, roughly 1.4× ONESPAWORLD HOLDINGS Ltd). HAEMONETICS CORP runs the higher net margin — 13.2% vs 5.0%, a 8.2% gap on every dollar of revenue. On growth, ONESPAWORLD HOLDINGS Ltd posted the faster year-over-year revenue change (11.5% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $14.9M). Over the past eight quarters, ONESPAWORLD HOLDINGS Ltd's revenue compounded faster (7.1% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
HAE vs OSW — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $242.1M |
| Net Profit | $44.7M | $12.1M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | 6.8% |
| Net Margin | 13.2% | 5.0% |
| Revenue YoY | -2.7% | 11.5% |
| Net Profit YoY | 19.3% | -16.2% |
| EPS (diluted) | $0.95 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $242.1M | ||
| Q3 25 | $327.3M | $258.5M | ||
| Q2 25 | $321.4M | $240.7M | ||
| Q1 25 | $330.6M | $219.6M | ||
| Q4 24 | $348.5M | $217.2M | ||
| Q3 24 | $345.5M | $241.7M | ||
| Q2 24 | $336.2M | $224.9M | ||
| Q1 24 | — | $211.2M |
| Q4 25 | $44.7M | $12.1M | ||
| Q3 25 | $38.7M | $24.3M | ||
| Q2 25 | $34.0M | $19.9M | ||
| Q1 25 | $58.0M | $15.3M | ||
| Q4 24 | $37.5M | $14.4M | ||
| Q3 24 | $33.8M | $21.6M | ||
| Q2 24 | $38.4M | $15.8M | ||
| Q1 24 | — | $21.2M |
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.9% | 6.8% | ||
| Q3 25 | 17.9% | 10.2% | ||
| Q2 25 | 16.8% | 9.2% | ||
| Q1 25 | 21.6% | 7.7% | ||
| Q4 24 | 16.9% | 7.9% | ||
| Q3 24 | 15.0% | 10.3% | ||
| Q2 24 | 11.8% | 8.4% | ||
| Q1 24 | — | 8.0% |
| Q4 25 | 13.2% | 5.0% | ||
| Q3 25 | 11.8% | 9.4% | ||
| Q2 25 | 10.6% | 8.3% | ||
| Q1 25 | 17.5% | 7.0% | ||
| Q4 24 | 10.8% | 6.6% | ||
| Q3 24 | 9.8% | 8.9% | ||
| Q2 24 | 11.4% | 7.0% | ||
| Q1 24 | — | 10.0% |
| Q4 25 | $0.95 | $0.12 | ||
| Q3 25 | $0.81 | $0.23 | ||
| Q2 25 | $0.70 | $0.19 | ||
| Q1 25 | $1.17 | $0.15 | ||
| Q4 24 | $0.74 | $0.13 | ||
| Q3 24 | $0.66 | $0.20 | ||
| Q2 24 | $0.74 | $0.15 | ||
| Q1 24 | — | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $16.3M |
| Total DebtLower is stronger | $1.2B | $84.0M |
| Stockholders' EquityBook value | $911.5M | $542.6M |
| Total Assets | $2.5B | $707.1M |
| Debt / EquityLower = less leverage | 1.34× | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $16.3M | ||
| Q3 25 | $296.4M | $29.6M | ||
| Q2 25 | $292.9M | $35.0M | ||
| Q1 25 | $306.8M | $22.6M | ||
| Q4 24 | $320.8M | $57.4M | ||
| Q3 24 | $299.3M | $48.8M | ||
| Q2 24 | $344.4M | $62.5M | ||
| Q1 24 | — | $65.4M |
| Q4 25 | $1.2B | $84.0M | ||
| Q3 25 | $1.2B | $85.2M | ||
| Q2 25 | $1.2B | $96.2M | ||
| Q1 25 | $1.2B | $97.4M | ||
| Q4 24 | — | $98.6M | ||
| Q3 24 | — | $98.7M | ||
| Q2 24 | — | $123.8M | ||
| Q1 24 | — | $138.6M |
| Q4 25 | $911.5M | $542.6M | ||
| Q3 25 | $849.2M | $552.8M | ||
| Q2 25 | $882.3M | $548.3M | ||
| Q1 25 | $820.8M | $530.6M | ||
| Q4 24 | $906.9M | $554.5M | ||
| Q3 24 | $878.9M | $540.1M | ||
| Q2 24 | $905.4M | $532.7M | ||
| Q1 24 | — | $515.5M |
| Q4 25 | $2.5B | $707.1M | ||
| Q3 25 | $2.4B | $732.6M | ||
| Q2 25 | $2.5B | $731.8M | ||
| Q1 25 | $2.5B | $708.7M | ||
| Q4 24 | $2.5B | $746.4M | ||
| Q3 24 | $2.5B | $734.0M | ||
| Q2 24 | $2.5B | $756.8M | ||
| Q1 24 | — | $763.6M |
| Q4 25 | 1.34× | 0.15× | ||
| Q3 25 | 1.44× | 0.15× | ||
| Q2 25 | 1.39× | 0.18× | ||
| Q1 25 | 1.49× | 0.18× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $20.0M |
| Free Cash FlowOCF − Capex | $87.2M | $14.9M |
| FCF MarginFCF / Revenue | 25.7% | 6.2% |
| Capex IntensityCapex / Revenue | 1.9% | 2.1% |
| Cash ConversionOCF / Net Profit | 2.09× | 1.65× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $68.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $20.0M | ||
| Q3 25 | $111.3M | $33.2M | ||
| Q2 25 | $17.4M | $20.3M | ||
| Q1 25 | $116.6M | $10.1M | ||
| Q4 24 | $43.8M | $16.6M | ||
| Q3 24 | $48.8M | $28.6M | ||
| Q2 24 | $-27.4M | $18.7M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $87.2M | $14.9M | ||
| Q3 25 | $106.3M | $27.6M | ||
| Q2 25 | $13.6M | $17.6M | ||
| Q1 25 | $100.9M | $8.4M | ||
| Q4 24 | $35.2M | $13.2M | ||
| Q3 24 | $39.4M | $27.5M | ||
| Q2 24 | $-33.1M | $17.6M | ||
| Q1 24 | — | $13.7M |
| Q4 25 | 25.7% | 6.2% | ||
| Q3 25 | 32.5% | 10.7% | ||
| Q2 25 | 4.2% | 7.3% | ||
| Q1 25 | 30.5% | 3.8% | ||
| Q4 24 | 10.1% | 6.1% | ||
| Q3 24 | 11.4% | 11.4% | ||
| Q2 24 | -9.8% | 7.8% | ||
| Q1 24 | — | 6.5% |
| Q4 25 | 1.9% | 2.1% | ||
| Q3 25 | 1.5% | 2.2% | ||
| Q2 25 | 1.2% | 1.1% | ||
| Q1 25 | 4.7% | 0.8% | ||
| Q4 24 | 2.5% | 1.5% | ||
| Q3 24 | 2.7% | 0.5% | ||
| Q2 24 | 1.7% | 0.5% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | 2.09× | 1.65× | ||
| Q3 25 | 2.88× | 1.36× | ||
| Q2 25 | 0.51× | 1.02× | ||
| Q1 25 | 2.01× | 0.66× | ||
| Q4 24 | 1.17× | 1.15× | ||
| Q3 24 | 1.44× | 1.33× | ||
| Q2 24 | -0.71× | 1.19× | ||
| Q1 24 | — | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
